Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy
Status:
Terminated
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the therapeutic response and safety of 3
oral dose levels of CCI-779, with placebo in subjects with active rheumatoid arthritis (RA)
who have been receiving stable doses of methotrexate (MTX) for at least 8 weeks.